AtaiBeckley Inc. (ATAI)
| Market Cap | 2.74B +182.9% |
| Revenue (ttm) | 4.47M +93.7% |
| Net Income | -668.19M |
| EPS | -2.14 |
| Shares Out | 370.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,313,858 |
| Open | 7.34 |
| Previous Close | 7.34 |
| Day's Range | 7.31 - 7.41 |
| 52-Week Range | 3.27 - 7.45 |
| Beta | 1.55 |
| Analysts | Hold |
| Price Target | 8.10 (+9.61%) |
| Earnings Date | Aug 11, 2026 |
About ATAI
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophr... [Read more]
Financial Performance
In 2025, AtaiBeckley's revenue was $4.09 million, an increase of 1227.60% compared to the previous year's $308,000. Losses were -$660.05 million, 342.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ATAI stock is "Hold." The 12-month stock price target is $8.1, which is an increase of 9.61% from the latest price.
News
AtaiBeckley downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Jay Olson downgraded AtaiBeckley (ATAI) to Perform from Outperform without a price target after Eli Lilly (LLY) agreed to acquire the company for $6.75 per share upfront cash…
AtaiBeckley downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded AtaiBeckley (ATAI) to Hold from Buy with a price target of $8, down from $12. The firm cites the pending acquisition by Eli Lilly for the downgrade.
AtaiBeckley Quarterly report: Q2 2026
AtaiBeckley has published its Q2 2026 quarterly earnings report on August 11, 2026.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 30, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio downgraded AtaiBeckley (ATAI) to Neutral from Buy with a price target of $7.50, down from $25, after Eli Lilly (LLY) agreed to acquire the company…
AtaiBeckley downgraded to Hold from Buy at Berenberg
Berenberg downgraded AtaiBeckley (ATAI) to Hold from Buy with a $7.45 price target after Eli Lilly (LLY) agreed to acquire the company for $6.75 per share upfront cash plus up…
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Thursday's announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma's increasing embrace of a long-stigmatized cla...
AtaiBeckley downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded AtaiBeckley (ATAI) to Hold from Buy without a price target after after Eli Lilly (LLY) agreed to acquire the company for $6.75 per share upfront cash plus…
Helus Pharma price target lowered to $45 from $48 at Guggenheim
Guggenheim lowered the firm’s price target on Helus Pharma (HELP) to $45 from $48 and keeps a Buy rating on the shares. The Eli Lilly (LLY) transaction for AtaiBeckley (ATAI)…
AtaiBeckley downgraded to Hold from Buy at Jefferies
Jefferies downgraded AtaiBeckley (ATAI) to Hold from Buy with a price target of $7.50, down from $10, after Eli Lilly (LLY) agreed to acquire the company for $6.75 per share…
AtaiBeckley downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded AtaiBeckley (ATAI) to Hold from Buy after Eli Lilly (LLY) agreed to acquire the company for $6.75 per share upfront cash plus up to $2.50 per share in…
AtaiBeckley downgraded to Hold from Buy at Canaccord
Canaccord downgraded AtaiBeckley (ATAI) to Hold from Buy with an $8 price target after Eli Lilly (LLY) announced a deal to acquire AtaiBeckley for $6.75 per share in cash plus…
AtaiBeckley downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded AtaiBeckley (ATAI) to Neutral from Buy after Eli Lilly (LLY) announced a deal to acquire AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share…
AtaiBeckley stock is soaring, and it has Eli Lilly to thank
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has...
AtaiBeckley downgraded to Hold from Buy at Maxim
Maxim downgraded AtaiBeckley (ATAI) to Hold from Buy after Eli Lilly (LLY) announced a deal to acquire the company for $6.75 per share in cash plus up to $2.50 per…
AtaiBeckley downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded AtaiBeckley (ATAI) to Neutral from Overweight after Eli Lilly (LLY) announced a deal to acquire the company for $6.75 per share in cash plus up to $2.50…
Why Is AtaiBeckley N.V. (ATAI) Stock Up Today?
AtaiBeckley N.V. ($ATAI) stock surged on Thursday after the clinical-stage biopharmaceutical company announced an acquisition agreement with global pharmaceutical firm Eli Lilly ($LLY). Under the term...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine. Madison Muller has more on "Bloomberg Open Inte...
AtaiBeckley downgraded to Hold from Buy at Needham
Needham downgraded AtaiBeckley (ATAI) to Hold from Buy without a price target after Eli Lilly announced a deal to acquire AtaiBeckley for $6.75 per share in cash plus up to…
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.
AtaiBeckley Proxy statement: Proxy filing
AtaiBeckley filed a proxy statement on July 16, 2026, providing details for shareholder voting and corporate governance matters.